2019 Novel Coronavirus Disease (COVID-19) in patients with Inflammatory Bowel Diseases.
Aliment Pharmacol Ther. 2020 May 02;:
Authors: Taxonera C, Sagastagoitia I, Alba C, Mañas N, Olivares D, Rey E
BACKGROUND: Data on patients with inflammatory bowel diseases (IBD) who have had 2019 novel coronavirus (SARS-CoV-2) disease (COVID-19) are lacking.
AIM: To report the clinical characteristics, including gastrointestinal symptoms, of COVID-19 in IBD patients, and to assess the risk of COVID-19 in IBD.
METHODS: This case series included consecutive IBD patients with laboratory-confirmed COVID-19. Age-adjusted cumulative incidences were compared with the general population in the Madrid region.
RESULTS: Through April 8, 12 patients of 1918 IBD patients were diagnosed of COVID-19. The average age was 52 years, 75% of the patients were female, and 58.3% had Crohn's disease. Seven patients (58%) were on maintenance treatment with immunomodulators/biologics, of these 4 with combined therapy (33%). Eight patients (66%) required hospitalization (1 intensive care unit admission, and 2 deaths), and 4 patients were isolated at home. Nine patients had diarrhoea ranging between 4-10 loose stools per day (mean 5.4, SD 1.6). In 5 patients (42%) diarrhoea was a presenting symptom. In 2 patients, diarrhoea was the only symptom at debut. Cumulative incidence of COVID-19 was 6.1 per 1000 IBD patients. IBD patients had a lower adjusted incidence ratio of COVID-19 (OR 0.74, 95% CI 0.70-0.77; p<0.001), and a similar associated mortality ratio (OR 0.95, 95% CI: 0.84-1.06; p=0.36), compared with the general population.
CONCLUSIONS: IBD patients do not have an increased risk of COVID-19 and associated mortality compared with the general population. In many IBD patients diarrhoea was a presenting symptom, and sometimes, was the only symptom at onset of COVID-19.
PMID: 32359205 [PubMed - as supplied by publisher]